4-(2-methanesulfonyl-4-methoxycarbonyl-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester | 1204331-16-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-methanesulfonyl-4-methoxycarbonyl-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-(4-(methoxycarbonyl)-2-(methylsulfonyl)phenyl)-5,6-dihydropyridine-1(2h)-carboxylate；tert-butyl 4-(4-methoxycarbonyl-2-methylsulfonylphenyl)-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 1204331-16-7
• 化学式: C₁₉H₂₅NO₆S
• 分子量: 395.477
• InChiKey: FVCJRUKKHKAQKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  98.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(2-methanesulfonyl-4-methoxycarbonyl-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 在 二氧化铂 作用下， 以to afford the desired product (2.00 g, 73%)的产率得到4-(2-methanesulfonyl-4-methoxycarbonyl-phenyl)piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors

  摘要：

  本发明揭示了化合物(I)和组合物，它们是钠质子交换器亚型-1（NHE-I）的抑制剂。同时还揭示了使用和制备这些化合物的方法。

  公开号：

  US20110118262A1
• 作为产物：
  描述：

  4-溴-3-甲基磺酰基苯甲酸甲酯 、 N-Boc-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以68%的产率得到4-(2-methanesulfonyl-4-methoxycarbonyl-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Identification of a Potent Sodium Hydrogen Exchanger Isoform 1 (NHE1) Inhibitor with a Suitable Profile for Chronic Dosing and Demonstrated Cardioprotective Effects in a Preclinical Model of Myocardial Infarction in the Rat

  摘要：

  Sodium-hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed transmembrane ion channel responsible for intracellular pH regulation. During myocardial ischemia, low pH activates NHE1 and causes increased intracellular calcium levels and aberrant cellular processes, leading to myocardial stunning, arrhythmias, and ultimately cell damage and death. The role of NHE1 in cardiac injury has prompted interest in the development of NHE1 inhibitors for the treatment of heart failure. This report outlines our efforts to identify a compound suitable for once daily, oral administration with low drug-drug interaction potential starting from NHE1 inhibitor sabiporide. Substitution of a piperidine for the piperazine of sabiporide followed by replacement of the pyrrole moiety and subsequent optimization to improve potency and eliminate off-target activities resulted in the identification of N-[4-(1-acetyl-piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine (60). Pharmacological evaluation of 60 revealed a remarkable ability to prevent ischemic damage in an ex vivo model of ischemia reperfusion injury in isolated rat hearts.

  DOI：

  10.1021/jm300601d

文献信息

• Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
  申请人：Bentzien Joerg Martin

  公开号：US20110118262A1

  公开（公告）日：2011-05-19

  Disclosed are compounds of formula (I) and compositions of the present invention which are inhibitors of the sodium proton exchanger isoform-1 (NHE-I). Also disclosed are methods of using and making the same.

  本发明揭示了化合物(I)和组合物，它们是钠质子交换器亚型-1（NHE-I）的抑制剂。同时还揭示了使用和制备这些化合物的方法。
• Identification of a Potent Sodium Hydrogen Exchanger Isoform 1 (NHE1) Inhibitor with a Suitable Profile for Chronic Dosing and Demonstrated Cardioprotective Effects in a Preclinical Model of Myocardial Infarction in the Rat
  作者：John D. Huber、Jörg Bentzien、Stephen J. Boyer、Jennifer Burke、Stéphane De Lombaert、Christian Eickmeier、Xin Guo、James V. Haist、Eugene R. Hickey、Paul Kaplita、Morris Karmazyn、Raymond Kemper、Charles A. Kennedy、Thomas Kirrane、Jeffrey B. Madwed、Elizabeth Mainolfi、Nelamangara Nagaraja、Fariba Soleymanzadeh、Alan Swinamer、Anne B. Eldrup

  DOI：10.1021/jm300601d

  日期：2012.8.23

  Sodium-hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed transmembrane ion channel responsible for intracellular pH regulation. During myocardial ischemia, low pH activates NHE1 and causes increased intracellular calcium levels and aberrant cellular processes, leading to myocardial stunning, arrhythmias, and ultimately cell damage and death. The role of NHE1 in cardiac injury has prompted interest in the development of NHE1 inhibitors for the treatment of heart failure. This report outlines our efforts to identify a compound suitable for once daily, oral administration with low drug-drug interaction potential starting from NHE1 inhibitor sabiporide. Substitution of a piperidine for the piperazine of sabiporide followed by replacement of the pyrrole moiety and subsequent optimization to improve potency and eliminate off-target activities resulted in the identification of N-[4-(1-acetyl-piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine (60). Pharmacological evaluation of 60 revealed a remarkable ability to prevent ischemic damage in an ex vivo model of ischemia reperfusion injury in isolated rat hearts.